ATsens
ATsens is a South Korean medical device company developing the AT-Patch, a wearable continuous ECG monitor providing up to 14 days of monitoring. It serves hospitals, cardiology clinics, and ambulatory cardiac monitoring services globally through distributors spanning 31 countries.
- Company typePrivate
- Founded2017
- HeadquartersSeongnam, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What ATsens does
ATsens is a South Korean medical device company founded in September 2017 that develops wearable continuous ECG monitoring solutions for cardiology. Its flagship product, AT-Patch, is a waterproof single-lead ECG patch capable of recording up to 14 days of continuous cardiac monitoring, materially exceeding the 24–48 hour duration of conventional Holter monitors. The company serves hospitals, cardiology departments, ambulatory cardiac monitoring services, and remote patient monitoring platforms globally, with active shipments to 10 countries and distributor contracts spanning 31 countries including South Korea, the US, Japan, the UK, Germany, Greece, Brazil, Kuwait, and Poland.
The company's product architecture is centered on the AT-Heart integrated solution: AT-Patch (the 13g wearable device with IP57 waterproof rating and Bluetooth connectivity), AT-Note (a smartphone app providing real-time ECG viewing and symptom logging), and AT-Report (proprietary ECG analysis software using two-step classification algorithms to detect 17 arrhythmia types, FDA-cleared in May 2025). AT-Monitoring extends the platform to real-time in-hospital patient monitoring via Gateway-to-Cloud infrastructure with Nurses' Station alarm functionality. ATsens holds 34 healthcare patents (13 registered) including proprietary biosensor chip technology and signal processing IP. The company is broadening its sensing footprint via the AT-Heart Platform roadmap to encompass respiratory rate, body temperature, SpO2, continuous blood pressure, and continuous glucose monitoring.
ATsens generates revenue primarily through B2B sale of AT-Patch hardware via a tiered global distributor network. Pricing is quote-based with multi-year enterprise contracts; major commitments include a five-year exclusive Japan Lifeline distribution contract (~27.8B KRW, signed December 2021), a three-year US supply agreement worth approximately $370M USD covering 450,000 units (signed July 2025), and a UK NHS Supply Chain partnership enabling procurement by ~1,978 NHS facilities. Secondary revenue streams include AT-Report software, AT-Note app subscriptions, AT-Monitoring services, and Korean insurance reimbursement (EX871, approved September 2025). Revenue is projected to grow from approximately KRW 6B currently to KRW 30B+ by 2027, and the company is preparing for a KOSDAQ listing.
ATsens firmographics
Firmographics- Name
- ATsens
- Legal name
- 주식회사 에이티센스 (ATsens Co., Ltd.)
- Website
- https://atsens.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- ATsens is a South Korean medical device company developing the AT-Patch, a wearable continuous ECG monitor providing up to 14 days of monitoring. It serves hospitals, cardiology clinics, and ambulatory cardiac monitoring services globally through distributors spanning 31 countries.
- Ownership category
- akta.pro rank
ATsens industry classification
Industry- Product category
- Wearable Cardiac Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
- akta.pro secondary industries
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Cardiology Telemedicine Platforms (HLALAGAB)
Keywords
Where ATsens is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
ATsens business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- AT-Patch Hardware Sales: Sale of wearable ECG monitoring devices (AT-Patch) to healthcare providers, hospitals, and through distributor networks globally. Primary revenue driver with major three-year supply contract covering 450,000 units.
- Software and Monitoring Services: Recurring revenue from AT-Note app, AT-Report analysis software, and AT-Monitoring real-time patient monitoring services, likely sold as subscriptions or per-report fees alongside hardware.
- B2B Enterprise Contracts: Large-scale supply agreements with institutional buyers such as the three-year $370M US distributor contract and UK NHS Supply Chain agreement, providing predictable recurring revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | B2B Enterprise / Institutional Pricing |
Go-to-market motion3 records
Distribution channels9 records
Marketing channels3 records
ATsens product offering
Product offeringCore offering
ATsens manufactures and sells the AT-Patch, a waterproof wearable single-lead ECG monitor that records up to 14 days of continuous cardiac data, paired with the AT-Note smartphone application for real-time ECG viewing, the AT-Report AI-powered analysis software for arrhythmia detection, and the AT-Monitoring real-time in-hospital patient monitoring platform. The integrated AT-Heart solution is sold to hospitals, cardiology clinics, healthcare systems, and ambulatory cardiac monitoring service providers globally through direct enterprise sales and distributor networks.
Product overview
ATsens offers a modular platform-based product architecture centered on the AT-Heart total ECG monitoring solution. The core portfolio consists of three integrated components: AT-Patch (wearable patch-type ECG device for up to 14-day continuous monitoring), AT-Note (Bluetooth-connected smartphone app for real-time ECG viewing and symptom logging), and AT-Report (proprietary AI-powered ECG analysis software with FDA clearance). These are complemented by AT-Monitoring (real-time in-hospital patient monitoring) and the evolving AT-Heart Platform (expanding to cover total heartcare including prediction and prevention). The company is also developing additional vital sign sensing technologies including respiratory rate, body temperature, SpO2, continuous blood pressure, and continuous glucose monitoring.
Differentiator
Problem solved
Functional benefit
Brands
- AT-Heart: Total ECG monitoring solution consisting of AT-Patch (device), AT-Note (smartphone app), and AT-Report (analysis software) for long-term continuous ECG monitoring.
- AT-Patch
- AT-Note
- AT-Report
- AT-Monitoring
Products and services
- AT-Patch Wearable patch-type long-term continuous ECG (Holter) monitor for detecting intermittent arrhythmias. Disposable, single-lead (Lead II) device with up to 14-day monitoring capability, IP44/IP57 waterproof rating, 13g weight, and no charging or electrode replacement required during monitoring period. Sold to hospitals, cardiology departments, and healthcare providers for arrhythmia detection, atrial fibrillation screening, and cryptogenic stroke workup.
- AT-Note Smartphone application providing real-time ECG viewer via Bluetooth connectivity and symptom recording functionality. Displays real-time ECG data and 3-axis motion sensor data from AT-Patch, allowing patients to log symptoms during abnormal cardiac events. Used by patients wearing the AT-Patch device under clinical supervision.
- AT-Report ECG analysis software applying proprietary two-step classification algorithms. Enables medical institutions to analyze long-term ECG data efficiently, detect 17 types of arrhythmias, generate doctor-centric final reports with ECG strips, and export to PDF. FDA-cleared under Enhanced Level of Concern criteria for clinical use by medical professionals.
- AT-Monitoring Real-time patient monitoring solution for hospitalized patients. AT-Patch transmits ECG signals via Bluetooth to Gateway, which sends data to Cloud for monitoring at Nurses' Station. Includes arrhythmia alarm functionality for clinical staff. Used by hospitals for inpatient cardiac monitoring.
- AT-Heart Solution Total integrated ECG monitoring solution comprising AT-Patch (device), AT-Note (smartphone app), and AT-Report (analysis software). Enables long-term continuous ECG monitoring for up to 14 days with real-time viewing and AI-powered analysis. Marketed to hospitals and cardiology practices as a complete end-to-end cardiac monitoring platform.
Companies that use ATsens
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
ATsens technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature5 records
ATsens partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered minor, core and secondary.
- Nel Animal Medical CenterminorMOU signed 2025 for joint research and development of pet wearable ECG monitoring technology, extending ATsens' core wearable ECG technology into the veterinary animal health market.
- People & TechnologyminorMOU signed 2025 for real-time patient monitoring collaboration, focused on integrating ATsens' ECG monitoring technology with broader patient monitoring platforms.
- Hanmi PharmaceuticalcoreDomestic Korean distribution agreement signed 2022 for AT-Patch ECG monitoring device distribution within South Korea, utilizing Hanmi Pharmaceutical's established pharmaceutical and medical device distribution infrastructure.
- UK NHS Supply ChaincoreSupply chain agreement established 2022 with NHS Supply Chain, the procurement and supply organization for the UK National Health Service, enabling AT-Patch ECG devices to be procured through the NHS supply chain.
- DCM DOLMED S.A. (Poland)secondarySupply MOU signed 2022 for ECG patch supply to Poland through DCM DOLMED S.A., a Polish medical device distributor.
- Kuwait DMC (AI Dabbous Medical Company)secondaryExport contract signed 2022 for AT-Patch distribution in Kuwait through AI Dabbous Medical Company (Kuwait DMC), a Kuwait-based medical device distributor.
- GS GlobalcoreNon-exclusive distribution MOU signed 2021 for North American market entry. Expanded in July 2025 with a three-year supply contract covering approximately 450,000 units (~$370M USD), with initial delivery of ~100,000 units scheduled for 2026.
- Japan LifelinecoreDistribution agreement signed 2021 for AT-Patch product distribution in Japan, leveraging Japan Lifeline's established medical device distribution network and regulatory relationships in the Japanese market.
- EnaMed (Greece)secondaryExport contract signed 2021 for AT-Patch distribution in Greece through EnaMed, a Greek medical device and healthcare distributor.
- Pratixia (Brazil)secondaryExport contract signed 2021 for AT-Patch distribution in Brazil through Pratixia, a Brazilian medical device distributor.
- Chungnam National University Sejong HospitalcoreSmart hospital platform collaboration established 2021, integrating AT-Patch ECG monitoring into the hospital's smart hospital digital infrastructure for enhanced cardiac care pathways.
- Seoul National University Bundang HospitalcoreClinical validation partnership for AT-Patch technology, conducting clinical studies and real-world evidence generation to support regulatory submissions and clinical adoption.
- Kyungpook National University HospitalcoreClinical validation partnership for AT-Patch technology, supporting clinical evidence generation for arrhythmia detection and cardiac monitoring applications.
- iMarketkoreasecondaryDomestic Korean distribution partnership established 2020 for AT-Patch distribution within South Korea.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
ATsens competitors and assessment
Company assessmentBroad incumbents
- Mindray: China-based global medical device manufacturer offering patient monitoring, ECG, and cardiology diagnostic equipment across emerging and developed markets. Competes with ATsens in the multi-vital signs monitoring category where ATsens is expanding (AT-Heart Platform roadmap).
- Spacelabs Healthcare: Spacelabs (an OSI Systems company) manufactures patient monitoring and cardiac diagnostic equipment, including Holter analysis and ambulatory ECG systems. Overlaps with ATsens in clinical cardiac monitoring for hospital and ambulatory settings.
- Preventice Solutions (Boston Scientific): Preventice (acquired by Boston Scientific in 2022) developed the BodyGuardian series of remote cardiac monitors, directly competitive with AT-Patch. Now operates within Boston Scientific's broader cardiac diagnostics portfolio, representing a large incumbent with similar patch/Holter technology plus broader infrastructure.
- Philips (BioTel Heart): Philips acquired BioTelemetry in 2021, integrating MCOT (Mobile Cardiac Outpatient Telemetry) and LifeWatch into its Connected Care segment. BioTel Heart is a major US patch/cardiac monitoring service with established reimbursement, competing head-to-head with ATsens in the same clinical use cases.
- Medtronic: Medtronic offers the SEEQ Mobile Cardiac Telemetry system and LINQ insertable cardiac monitor, representing a large incumbent in cardiac diagnostics with deeper R&D and direct sales reach. Competes with ATsens in ambulatory monitoring and arrhythmia detection across hospital and outpatient channels.
Emerging players
- Biotricity: Biotricity develops wearable cardiac monitoring devices (Bioflux MCT, Biolife) targeting ambulatory and remote patient monitoring use cases. Smaller and earlier-stage than ATsens but addresses overlapping clinical indications with patch-based continuous monitoring.
Direct peers
- AliveCor: AliveCor offers KardiaMobile ECG devices (single-lead and 6-lead) paired with AI-based arrhythmia detection algorithms and a smartphone-connected workflow. Comparable to ATsens in the AI-powered ECG analysis software and consumer/clinical hybrid positioning, though more focused on spot recording vs continuous monitoring.
- iRhythm Technologies: iRhythm is the most direct competitor with its Zio long-term continuous ECG patch monitor and central lab analysis service. ATsens explicitly competes against iRhythm with AT-Patch and the on-premise AT-Report model positioning as an alternative to Zio's central lab interpretation service.
Regional players
- Nihon Kohden: Leading Japanese medical electronics company specializing in patient monitoring, ECG, and neurology diagnostics. Operates broadly in the same clinical space as ATsens but primarily within Japan; competes with AT-Patch in Japanese hospitals via established distribution and broader installed base.
- Fukuda Denshi: Japan-based manufacturer of ECG Holter monitors, patient monitors, and cardiology diagnostic equipment with deep PMDA-cleared product portfolio. Most directly comparable to ATsens in the Japanese market where ATsens has secured Japan Lifeline partnership; a potential alternative supply partner or competitive threat.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights8 records
Customer concentration
ATsens social profiles
Digital presenceATsens compliance and trust
Trust signalCompliance5 records
ATsens financial estimates
Financial estimateRevenue estimate
Valuation estimate
ATsens leadership team
Management profileNumber of profiles
Profiles3 records
ATsens funding detail
Funding detailFunding overview
Funding rounds3 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ATsens M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ATsens
What does ATsens do?
ATsens manufactures and sells the AT-Patch, a waterproof wearable single-lead ECG monitor that records up to 14 days of continuous cardiac data, paired with the AT-Note smartphone application for real-time ECG viewing, the AT-Report AI-powered analysis software for arrhythmia detection, and the AT-Monitoring real-time in-hospital patient monitoring platform. The integrated AT-Heart solution is sold to hospitals, cardiology clinics, healthcare systems, and ambulatory cardiac monitoring service providers globally through direct enterprise sales and distributor networks.
Is ATsens a public or private company?
ATsens is a private company. It is classified as venture growth investor backed and is currently operating.
When was ATsens founded?
ATsens was founded in 2017. It employs 51 to 100 people.
Where is ATsens based?
ATsens is headquartered in Seongnam, South Korea, in the Asia region.
How does ATsens make money?
Three revenue lines are on record. AT-Patch Hardware Sales are the primary driver. The others are software and Monitoring Services and B2B Enterprise Contracts.
Who are ATsens's main competitors?
Broad incumbents on record are Mindray, Spacelabs Healthcare, Preventice Solutions (Boston Scientific), Philips (BioTel Heart) and Medtronic. Biotricity is listed as an emerging player. Direct peers are AliveCor and iRhythm Technologies. Regional players are Nihon Kohden and Fukuda Denshi.
Does ATsens have an API?
No public API is recorded for ATsens.
What industry is ATsens in?
ATsens's product category is Wearable Cardiac Monitoring Devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration). Its NAICS code is 334510 and its SIC code is 3845.